YR
Yasmeen Rahimi Piper Sandler Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Prothena Corp
PRTA
$460M
| $8.55 | $15 |
75%
upside
| Overweight | 8 days ago |
|
|
IVA
2
Inventiva
IVA
$775M
| $5.57 | $26 |
367%
upside
| Overweight | 9 days ago |
|
|
VRNA
3
Verona Pharma
VRNA
$9.2B
| $106.31 | $160 |
51%
upside
| Overweight | 2 months ago |
|
|
TVRD
4
Tvardi Therapeutics, Inc. Common Stock
TVRD
$292M
| $31.11 | $78 |
151%
upside
| Overweight | 2 months ago |
|
5
Soleno Therapeutics
SLNO
$3.71B
| $69.77 | $145 |
108%
upside
| Overweight | 4 months ago |
|
6
Edgewise Therapeutics
EWTX
$1.64B
| $15.57 | $51 |
228%
upside
| Overweight | 5 months ago |
|
7
Lexicon Pharmaceuticals
LXRX
$396M
| $1.09 | $6 |
450%
upside
| Overweight | 6 months ago |
|
|
DRUG
8
Bright Minds Biosciences
DRUG
$299M
| $42.24 | $93 |
120%
upside
| Overweight | 7 months ago |
|
|
UPB
9
Upstream Bio, Inc. Common Stock
UPB
$1.08B
| $19.97 | $75 |
276%
upside
| Overweight | 10 months ago |
|
10
Nektar Therapeutics
NKTR
$764M
| $40.18 | $105 |
161%
upside
| Overweight | 10 months ago |
|
11
NewAmsterdam Pharma
NAMS
$3.04B
| $27 | $37 |
37%
upside
| Overweight | 11 months ago |
|
12
Crinetics Pharmaceuticals
CRNX
$3.35B
| $35.61 | $97 |
172%
upside
| Overweight | 1 year ago |
|
13
Praxis Precision Medicines
PRAX
$986M
| $46.85 | $270 |
476%
upside
| Overweight | 1 year ago |
|
|
TECX
14
Tectonic Therapeutic, Inc. Common Stock
TECX
$314M
| $16.80 | $76 |
352%
upside
| Overweight | 1 year ago |
|
15
Altimmune
ALT
$334M
| $3.78 | $25 |
561%
upside
| Overweight | 1 year ago |
|
16
Benitec Biopharma
BNTC
$365M
| $13.91 | $30 |
116%
upside
| Overweight | 1 year ago |
|
17
Design Therapeutics
DSGN
$367M
| $6.45 | $12 |
86%
upside
| Overweight | 1 year ago |
|
18
Korro Bio
KRRO
$312M
| $33.18 | $180 |
443%
upside
| Overweight | 1 year ago |
|
19
Gossamer Bio
GOSS
$668M
| $2.94 | $15 |
410%
upside
| Overweight | 1 year ago |
|
20
Madrigal Pharmaceuticals
MDGL
$9.65B
| $432.89 | $336 |
22%
downside
| Overweight | 1 year ago |
|
21
Savara
SVRA
$643M
| $3.72 | $16 |
330%
upside
| Overweight | 1 year ago |
|
22
AnaptysBio
ANAB
$613M
| $21.90 | $80 |
265%
upside
| Overweight | 1 year ago |
|
23
Structure Therapeutics
GPCR
$1.27B
| $22.08 | $93 |
321%
upside
| Overweight | 1 year ago |
|
24
Tourmaline Bio
TRML
$687M
| $26.74 | $65 |
143%
upside
| Overweight | 1 year ago |
|
25
Immunovant
IMVT
$2.99B
| $17.14 | $57 |
233%
upside
| Overweight | 1 year ago |
|